LogicBio marks week’s third IPO to miss price target

LogicBio Therapeutics Inc. (NASDAQ:LOGC) priced its IPO below its proposed range late Thursday, joining two other biotechs that missed their target price this week. But shares of the genome editing company jumped $1.90

Read the full 334 word article

User Sign In